Literature DB >> 30008066

Tumor-Associated T-Lymphocytes and Macrophages are Decreased in Endometrioid Endometrial Carcinoma with MELF-Pattern Stromal Changes.

Dmitry Aleksandrovich Zinovkin1, Md Zahidul Islam Pranjol2, Il'ya Andreevich Bilsky3, Valeriya Alexandrovna Zmushko3.   

Abstract

Microcystic, elongated, fragmented (MELF)-pattern is an unusual morphology of myometrial invasive front in endometrioid endometrial carcinoma (EA). The aim of the study was to investigate potential correlation between MELF-pattern and peritumoral inflammatory immune response. A total of 96 out of 368 patients were included in this study. CD3, CD20, CD57. CD68 and S100 markers were used for the detection of tumor-associated T-lymphocytes (TAT), tumor-associated B-lymphocytes (TAB), tumor-associated NK-lymphocytes (NK), tumor-associated macrophages and dendritic cells respectively. Mann-Whitney tests, receiver operating characteristic (ROC) curve analysis, and Spearman correlation were used as methods for statistical analyses. Odds ratio with 95% confidence interval (95% CI) was determined with the use of a logistic regression model. A p < 0.05 was considered statistically significant. Our results suggested that the number of CD3 and CD68 cells were significantly lower (p < 0.001) in cases of endometrioid carcinoma with MELF-pattern. A significant correlation between the presence of MELF-pattern and decrease of CD3 positive T-lymphocytes (r = 0.691; p < 0.001) was also observed. Additionally, we found an inverse correlation between the presence of MELF-pattern and TAM (r = 0.568; p = 0.001). Therefore, our data suggest that MELF-pattern may be associated with EA stroma fibrosis that contains immune cells infiltration and demonstrated a decrease in the number of TAT and TAM cells. This may indicate the poor clinical prognosis of this disease.

Entities:  

Keywords:  Cancer stroma; Endometrioid endometrial carcinoma; MELF-pattern; Tumor immunoenvironment

Year:  2018        PMID: 30008066      PMCID: PMC6250614          DOI: 10.1007/s12307-018-0213-5

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  29 in total

1.  T lymphocytes (CD3) may participate in the recurrence of cervical intraepithelial neoplasia grade III.

Authors:  P J Maluf; M A Michelin; R M Etchebehere; S J Adad; E F C Murta
Journal:  Arch Gynecol Obstet       Date:  2008-03-15       Impact factor: 2.344

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 4.  Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.

Authors:  Etienne Becht; Nicolas A Giraldo; Claire Germain; Aurélien de Reyniès; Pierre Laurent-Puig; Jessica Zucman-Rossi; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Adv Immunol       Date:  2016-01-29       Impact factor: 3.543

5.  Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion.

Authors:  Colin J R Stewart; Maxine L Crook
Journal:  Int J Gynecol Pathol       Date:  2010-11       Impact factor: 2.762

Review 6.  Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; David G DeNardo
Journal:  Cancer Immunol Immunother       Date:  2017-04-27       Impact factor: 6.968

7.  Tumor-Infiltrated Lymphocytes, Macrophages, and Dendritic Cells in Endometrioid Adenocarcinoma of Corpus Uteri as Potential Prognostic Factors: An Immunohistochemical Study.

Authors:  Dmitry Zinovkin; Md Zahidul Islam Pranjol
Journal:  Int J Gynecol Cancer       Date:  2016-09       Impact factor: 3.437

8.  Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.

Authors:  Estrella Mariel Levy; Michele Bianchini; Erika María Von Euw; Maria Marcela Barrio; Alicia Inés Bravo; David Furman; Enzo Domenichini; Carlos Macagno; Victor Pinsky; Cinzia Zucchini; Luisa Valvassori; José Mordoh
Journal:  Int J Oncol       Date:  2008-03       Impact factor: 5.650

9.  Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition.

Authors:  Colin J R Stewart; Leonie Little
Journal:  Histopathology       Date:  2009-07       Impact factor: 5.087

Review 10.  Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.

Authors:  Xiang Zheng; Kati Turkowski; Javier Mora; Bernhard Brüne; Werner Seeger; Andreas Weigert; Rajkumar Savai
Journal:  Oncotarget       Date:  2017-07-18
View more
  4 in total

1.  Endometrial Tumour Microenvironment.

Authors:  Carlos Casas-Arozamena; Miguel Abal
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathway.

Authors:  Bei Zhou; Yun Yang; Cuiping Li
Journal:  Onco Targets Ther       Date:  2019-04-04       Impact factor: 4.147

3.  High Expression of Galectin-1, VEGF and Increased Microvessel Density Are Associated with MELF Pattern in Stage I-III Endometrioid Endometrial Adenocarcinoma.

Authors:  Dmitry Aleksandrovich Zinovkin; Sergey Leonidovich Achinovich; Mikhail Grigoryevich Zubritskiy; Jacqueline Linda Whatmore; Md Zahidul Islam Pranjol
Journal:  J Pathol Transl Med       Date:  2019-06-27

4.  Quantitative diffusion and perfusion MRI in the evaluation of endometrial cancer: validation with histopathological parameters.

Authors:  Serena Satta; Miriam Dolciami; Veronica Celli; Francesca Di Stadio; Giorgia Perniola; Innocenza Palaia; Angelina Pernazza; Carlo Della Rocca; Stefania Rizzo; Carlo Catalano; Silvia Capuani; Lucia Manganaro
Journal:  Br J Radiol       Date:  2021-06-16       Impact factor: 3.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.